BCMA CAR T cells / University College London - LARVOL DELTA

Real-world outcomes with CAR-T therapy in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective Study using trinetx database (ASH 2025) - "Introduction:Two BCMA CAR-T cell therapies ie Idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (cilta-cel)have been approved for use in relapsed/refractory multiple myeloma (RRMM)...For lymphodepletion agents, cyclophosphamide wasused in 83% of the renal impairment group vs 76% non-renal impairment group, Fludarabine was used in78% vs 70%, bendamustine was used in 4% vs 5%...Patients with renal failure have comparable outcomes and a comparable safety profile with CAR-T celltherapy in RRMM hence renal impairment should not exclude this cohort from CAR-T eligibility."

Real-world • Real-world evidence • Retrospective data • Cardiovascular • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Neutropenia • Obesity • Pulmonary Disease • Renal Disease • Respiratory Diseases • Thrombocytopenia

MCARTY: A New Study Evaluating the Activity of Modular CAR T for mYeloma (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: University College, London | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2035 ➔ Mar 2029 | Trial primary completion date: Dec 2025 ➔ Mar 2029

Enrollment open • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. (PubMed, Lancet Oncol) - "In this Review, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonisation and Guidelines Committee provides recommendations on the management of CAR T-cell associated neurological complications that occur after treatment with the licensed CD19 and BCMA CAR T cells, as well as neurological toxicities that are emerging with CAR T cells in clinical trials for solid and haematological cancers. We address movement and neurocognitive toxicity, cranial nerve palsies, tumour inflammation-associated neurotoxicity, stroke, myelopathy, peripheral neuropathy, Guillain-Barré syndrome, fludarabine-associated neurotoxicity, and provide guidance on the psychological support for patients...The guidelines were developed based on the currently available literature and expert opinion. Recommendations are provided when possible, and areas for further research are highlighted to provide a framework to improve patient care."

Harmonization • Journal • Review • Cardiovascular • CNS Tumor • Hematological Disorders • Hematological Malignancies • Infectious Disease • Oncology • Pain • Solid Tumor • Transplantation

MCARTY: A New Study Evaluating the Activity of Modular CAR T for mYeloma (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: University College, London | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 (Yahoo Finance) - P1 | N=24 | MCARTY (NCT04795882) | "As of November 13, 2023 (data cut-off), 11 patients have been infused with either BCMA CAR at 50 million (n=3) or 150 million (n=3) cells, or AUTO8 at 50 million (n=3) or 150 million (n=2). At a median follow-up of 6 months we observed 100% response rate (ORR), with 3 PR, 1 VGPR, 7 CR/sCR (all evaluable MRD negative). Two patients remained in ongoing sCR > 12 months. No cases of ICANS or CRS ≥ Gr 3 were observed across all subjects during the period. While persistence data from the dual targeting cohort is immature, it demonstrates expansion of three CAR populations and suggests a trend to increased persistence of D8 BCMA CAR expressing T cells."

P1 data • Multiple Myeloma

OUTCOMES AFTER ANTI-BCMA CAR T-CELLS FOR MULTIPLE MYELOMA, A RETROSPECTIVE ANALYSIS ON BEHALF OF THE CTIWP OF THE EBMT (EBMT 2023) - "Therapy with the anti-BCMA CAR T-cell products ide-cel and cilta-cel translate into high response rates in patients with highly pretreated MM, including previous lines of treatment including autologous HCT, immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies. Furthermore, in patients that developed CRS, the majority developed grade 1-2 CRS and severe CRS appeared very uncommon. Overall, analysis of real-life data is important, regarding response, but also toxicities, in order to guide treatment choice; not only between available anti-BCMA CAR T-cells but also with regard to bispecific monoclonal antibodies that are increasingly available for patients with MM."

CAR T-Cell Therapy • Retrospective data • Hematological Malignancies • Immune Modulation • Inflammation • Multiple Myeloma • Oncology